Article
Inspection Readiness — The 90-Day CMC Preparation Framework
The companies that perform best in FDA inspections are not the ones that scramble in the two weeks before the investigator arrives — they are the ones that…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Inspection Readiness — The 90-Day CMC Preparation Framework
The companies that perform best in FDA inspections are not the ones that scramble in the two weeks before the investigator arrives — they are the ones that…
Article
3.2.S.2.2 Description of Manufacturing Process and Process Controls: Writing a Reviewable Route-of-Synthesis Narrative
"The description of the manufacturing process is insufficient to assess the controls in place for the critical steps identified."
Article
Module 3 Deficiency Patterns — Why CMC Packages Fail at First Review
The most expensive regulatory event in drug development is not a clinical hold — it is a Complete Response Letter issued because the CMC package FDA received could…
Article
3.2.S.2.1 Drug Substance Manufacturers: What FDA Expects Beyond a Site Name and Address
3.2.S.2.1 Drug Substance Manufacturers: What FDA Expects Beyond a Site Name and Address"
Article
ALCOA+ — What FDA Finds When It Opens Your Data Integrity records
When an FDA investigator opens your laboratory data system during an inspection, the first thing they are not looking for is whether your results pass specification — they…
Article
3.2.S.1 Drug Substance General Information: The Identity Foundation Every CMC Submission Must Get Right
FDA's most common opening question for a new drug substance file is not about impurities or stability — it is about identity. When the structural representation, nomenclature, and…
Article
FDA 483 Recurring Observations — Pattern Recognition for CMC Teams
FDA has cited laboratory controls as its most frequent drug manufacturing observation for 14 consecutive years. The problem is not that pharma companies do not know the regulation.…
Article
Water Dripping Onto Your API Production Floor Is Not a Maintenance Issue. It Is an FDA Enforcement Issue. Alchymars’ May 2026 Warning Letter Explains Why.
FDA's Warning Letter to Alchymars ICM SM Private Limited, issued May 21, 2026 (MARCS-CMS 724429), documents something that is rare in its physical vividness but entirely predictable in…
Article
The CMC Function in 2030 Why the Firms Investing in Regulatory Data Architecture Now Will Win
The regulatory submission of 2030 will not be a PDF with a table of contents. It will be structured data with narrative context — machine-readable, agency-queryable, and continuously…
Article
IDMP Implementation: What EU Marketing Authorization Holders Need to Know Now
IDMP is not a regulatory submission format. It is a data management commitment. The pharmaceutical companies that have treated it as a one-time registration exercise are discovering what…
Article
What FDA’s PQ/CMC Initiative Means for the Future of Structured CMC Submissions
FDA’s PQ/CMC program is developing structured, standardized approaches for selected pharmaceutical-quality information that is currently submitted in CTD Module 3 and Module 2.3. As of August 2026, the…
Article
AI-Enabled CMC: Where the Technology Actually Works and Where It Does Not (Yet)
Pharmaceutical AI is splitting into two categories: tools that have FDA-recognized regulatory frameworks and tools that do not. Knowing which is which determines whether your AI investment helps…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.